TY - JOUR
T1 - Outcome correlation of smear-positivity but culture-negativity during standard anti-tuberculosis treatment in Taiwan
AU - Chao, Wen Cheng
AU - Huang, Yi Wen
AU - Yu, Ming Chih
AU - Yang, Wen Ta
AU - Lin, Chou Jui
AU - Lee, Jen Jyh
AU - Huang, Ruay Ming
AU - Shieh, Chi Chang
AU - Chien, Shun Tien
AU - Chien, Jung Yien
N1 - Publisher Copyright:
© Chao et al.; licensee BioMed Central.
PY - 2015/2/18
Y1 - 2015/2/18
N2 - The appearance of smear-positivity but culture-negativity (SPCN) for acid-fast bacilli among sputum specimen is frequently found in pulmonary tuberculosis (TB) patients during treatment. This study aimed to investigate clinical risk factors, impacts on treatment course, and relapse pattern associated with sputum SPCN. Methods: We retrospectively enrolled 800 patients with culture-proven pulmonary TB who were receiving standard treatment and follow-up at six TB-referral hospitals in Taiwan between January 2006 and December 2007. Relevant patient characteristics and chemotherapy data were analyzed for associations with incidence of SPCN. Data from patients who relapsed within 3 years after completing treatment were analyzed for associations with SPCN during treatment. Results: Of the 800 subjects, 111 (13.8%) had sputum SPCN during treatment. Three factors were found to predict the development of SPCN; namely, high initial acid-fast staining grading (OR, 3.407; 95% CI, 2.090-5.553), cavitation on chest-X ray films (OR, 2.217; 95% CI, 1.359-3.615), and smoking (OR, 1.609; 95% CI, 1.006-2.841). Patients with SPCN had longer treatment duration (rifampicin: 284 ± 91 vs. 235 ± 69 days, <0.001; isoniazid: 289 ± 90 vs. 234 ± 69 days, < 0.001) than those without SPCN. Finally, the rate of relapse within 3 years of completing treatment was similar for groups with/without SPCN (2.7%, 3/111 vs. 1.0%, 7/689, respectively; = 0.15). Conclusions: In conclusion, severity of infection was a major risk factor for SPCN during treatment; however, the relapse rate within 3 years of completing treatment was not affected by the appearance of SPCN.
AB - The appearance of smear-positivity but culture-negativity (SPCN) for acid-fast bacilli among sputum specimen is frequently found in pulmonary tuberculosis (TB) patients during treatment. This study aimed to investigate clinical risk factors, impacts on treatment course, and relapse pattern associated with sputum SPCN. Methods: We retrospectively enrolled 800 patients with culture-proven pulmonary TB who were receiving standard treatment and follow-up at six TB-referral hospitals in Taiwan between January 2006 and December 2007. Relevant patient characteristics and chemotherapy data were analyzed for associations with incidence of SPCN. Data from patients who relapsed within 3 years after completing treatment were analyzed for associations with SPCN during treatment. Results: Of the 800 subjects, 111 (13.8%) had sputum SPCN during treatment. Three factors were found to predict the development of SPCN; namely, high initial acid-fast staining grading (OR, 3.407; 95% CI, 2.090-5.553), cavitation on chest-X ray films (OR, 2.217; 95% CI, 1.359-3.615), and smoking (OR, 1.609; 95% CI, 1.006-2.841). Patients with SPCN had longer treatment duration (rifampicin: 284 ± 91 vs. 235 ± 69 days, <0.001; isoniazid: 289 ± 90 vs. 234 ± 69 days, < 0.001) than those without SPCN. Finally, the rate of relapse within 3 years of completing treatment was similar for groups with/without SPCN (2.7%, 3/111 vs. 1.0%, 7/689, respectively; = 0.15). Conclusions: In conclusion, severity of infection was a major risk factor for SPCN during treatment; however, the relapse rate within 3 years of completing treatment was not affected by the appearance of SPCN.
KW - Cavity
KW - Relapse
KW - Severity
KW - Treatment
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=84924063082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924063082&partnerID=8YFLogxK
U2 - 10.1186/s12879-015-0795-1
DO - 10.1186/s12879-015-0795-1
M3 - Article
C2 - 25886042
AN - SCOPUS:84924063082
SN - 1471-2334
VL - 15
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 67
ER -